The Blood Matters program is underpinned by the Department’s values, vision, and priorities. Read more about the priorities on the Our priorities page.
The program aims to support best practice in all areas related to blood management safety and governance.
The content of these pages is intended for use by health care staff; clinical, quality, and scientific.
What's new
-
The latest STIR bulletin focuses on RhD immunoglobulin use in non-obstetric patients.
STIR Bulletin No.11 - RhD immunoglobulin use in non-obstetric patientsSTIR Bulletin No.11 - RhD immunoglobulin use in non-obstetric patientsSee more at Serious Transfusion Incident Reporting (STIR).
-
Blood Matters has developed a document comparing the new four-factor prothrombin complex concentrate Beriplex with the soon-to-be-discontinued three-factor prothrombin complex concentrate.
Comparison Prothrombinex Beriplex factsheet (Word)Comparison Prothrombinex Beriplex factsheet (PDF) -
Read the February newsletter.
Blood Matters on the Bench and Beyond February 2025Blood Matters on the Bench and Beyond February 2025Previous versions are available on Transfusion science and blood stewardship page.
-
The 2025 audit focuses on the pretransfusion patient identification and product check. Details of the audit are now available on Blood Matters audits.
-
The report is an overview of the Blood Matters program activities and plans intended for distribution to blood management committees (or equivalent).
February 2025 - Blood Management Committee reportFebruary 2025 - Blood Management Committee reportSee previous reports on Resources and education.
-
Following the release of Beriplex, a four-factor prothrombin complex concentrate, there has been an update to the recommendations for warfarin reversal.
For more information, see Clinical education resources on Resources and education – blood transfusion.
Reviewed 11 March 2025